Home
overview

The market for rare disease products  is continuously  growing, expecting to reach $176 billion by 2020, with a CGR of 10.5% just for orphan drugs – this is twice the growth rate of the overall prescription drug market (5.3% CGR from 2014-2020). 

Given this information, SMi are proud to announce our 9th Annual Orphan Drugs and Rare Diseases conference, aiming  to bring together solution providers, biotechnology companies, clinical researchers, regulatory professionals and charity leaders together to discuss possible ways to accelerative orphan drug development and access to rare disease patients, including the introduction of recent technologies and products to help aid the access of  orphan drugs.

We look forward to welcoming you to the conference this October.

Early registration is strongly advised to avoid disappointment.
 

 

 

HEAR about the success of orphan drug launches following the heavy involvement of patient advocacy programs

DISCUSS the potential changes in assessing the development of medicines across Europe

EXPLORE the future landscape orphan drugs following the market access and reimbursement challenges providers are currently facing.

 GAIN INSIGHT into the various challenges facing orphan drug development

CEOs, CSOs, Vice Presidents, Directors, Heads, Principals working in:

  • Medical Affairs
  • Medical Advisory
  • Clinical Operations
  • Rare Disease Research
  • Patient Advocacy
  • Commercial Officer
  • Orphan Drug Therapeutics
  • Healthcare
  • Regulatory  Affairs
  • Rare Disease Charity Officers

 

Previous attendees included:

AKU Society; AstraZeneca; BioMarin Europe Ltd; BRAINCURES; Chiesi Farmaceutici S. p. A.; Clintec International Ltd; Debra UK; Healx; HealX Limited; Incisive Health; JG Zebra Consulting; Luna Pharma Consulting Ltd; Mallinckrodt; MEDExpansion; Mereo BioPharma; MHRA; Minoryx Therapeutics S.L.; Muscular Dystrophy UK; Niemann-Pick UK; NSPM Limited; Pharma Innovation Consultancy GmbH; Pharm-Olam International; Pulse Infoframe; Rare Disease UK; Sanofi UK; Sosei Heptares; Takeda Chemical Industries Ltd; University College London; University Of Groningen; Vifor Pharma; Vitro software; Wilson Therapeutics AB; Zambon spa;

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Michael Page

Michael Page, Executive Director, Portfolio Products, Alexion Pharmaceuticals Inc
View Bio

9:10 Early access for orphan drugs

Tom Watson

Tom Watson, Executive Vice President, Bionical Emas
View Bio

• Cases of temporary market access approval and benefits to patients with no other available treatment options
• How orphan drug manufacturers can maneuver between the differences in legislation of early access in Europe alone.
• Success of integrated approaches to develop and robust early access and evidence generation plan, considering commercial availability and multiple stakeholder’s viewpoints
• Insights into the various circumstances where to be considered during the implementation of early access programs (EAPs), including the regulatory landscape and key considerations for their successful implementation.
 

9:50 Exploring different possible methods to assess real value of orphan drugs

Sheela Upadhyaya

Sheela Upadhyaya, Associate Director - Highly Specialised Technologies , NICE - National Institute for Health and Care Excellence
View Bio

• Discussing the success of NICE’s cost effective approach in putting new orphan drugs on the market
• Overview of new appraisal techniques, including HST (Highly Specialised Technology),
• Challenges faced by orphan drug product manufacturers
• Introduction of the budget impact threshold developed for assessment of ultra-orphan drugs

 

10:30 Morning Coffee

11:00 Collaborations in rare disease research and commercialisation

Katrin Jack

Katrin Jack, Sr. Manager Patient Access & Evidence Generation, Takeda Pharma AG
View Bio

• Discussing how rare disease research and commercialization differs due to the variety of cases
• More interlinks needed between patients, clinicians, scientists, authorities and industry professionals both nationally and internationally
• Addressing importance of close collaborations with patients when mapping out the patient’s journey
• Highlighting benefits of understanding rare disease
• Intervention of pharmaceutical companies to develop appropriate lifelong treatments
 



 

11:40 Drug repurposing – a lifeline for rare disease patients

Rick Thompson

Rick Thompson, CEO, Findacure
View Bio

• Exploring the commercial potential for drug repurposing and successes of rare disease patient groups in helping to drive these projects to the clinic
• Current developments in the field of social investment to fund generic drug repurposing and its potential for ultra-rare diseases
• Discussing how to encourage a research interest in rare and ultrarare diseases, potentially leading to the development of new treatments
 

12:20 Networking Lunch

13:20 Chiesi’s CASE STUDY: Holuclar

Sara Carlot

Sara Carlot, Global Medical Advisor - Rare Disease, Chiesi Farmaceutici S. p. A.
View Bio

• Introduction of stem cell-based therapies into the rare disease space
• Case study – The first EMA stem cell based approved therapy for treating LSCD (Limbal stem cell deficiency): Holoclar, what has been done until now and where are we
• Peculiarity of the product: the Holoclar Medical Service
 

14:00 A collaborative model to improve the success of translational research: a charity’s perspective

Annamaria Merico

Annamaria Merico, Head of Technology Transfer, Fondazione Telethon

• Enabling factors and challenges in the development of an advanced therapy medicinal product
• How a charity is assisting families participating in gene therapies
• Can we catalyse the development” in series” of multiple therapies for genetic diseases?
 

14:40 Afternoon Tea

15:10 Biology and biomarker-powered drug discovery and pipeline management

Krzysztof Potempa

Krzysztof Potempa, Founder and Director, BRAINCURES
View Bio

• Overview of Braincure’s discovery engine – a unique and biology-powered in silico approach to accelerate preclinical drug discovery
• Case study on the molecular framework of BDE, how it does not require data-training associated with AI
• Pipeline of translational opportunities for digital technology and low cost/high success precision medicine
 

15:50 How publicly-available data and AI can help prioritise rare disease and orphan drug clinical projects

Eddie Pease

Eddie Pease, CTO, PharmaForesight.ai
View Bio

• What we’ve learnt – the challenges of using publicly-available data
• The opportunities and challenges of AI in Pharma
• Particular challenges of predict rare disease outcomes
 

16:30 Chairman’s Closing Remarks and Close of Day One

Michael Page

Michael Page, Executive Director, Portfolio Products, Alexion Pharmaceuticals Inc
View Bio

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Rick Thompson

Rick Thompson, CEO, Findacure
View Bio

9:10 Overview of current orphan drug regulation

Michael Page

Michael Page, Executive Director, Portfolio Products, Alexion Pharmaceuticals Inc
View Bio

• Discussion on current state regulation of orphan drugs, and the level of scientific rigour needed for orphan drug approval (accepting small patient group studies and short studies)
• Assessing the importance of clinical evidence during the launch of an orphan drug, taking into account the difficultly in planning and executing clinical trials for rare/ultra-rare diseases.
• Synopsis of the evidence requirements before and after the registration and open access to a new drug
 

9:50 MoCA early dialogue between payers and manufacturers: An Opportunity to Improve Decision Making for Orphan Drugs in Europe?

Martina  Garau

Martina Garau, Associate Director, Office Of Health Economics
View Bio

• What is the MoCa process and its aim? Which parties are involved and what are the applications to date?
• What is the Transparent Value Framework, how is it used within MoCA, and how can it be improved?
• What are the advantages and disadvantages of participating in MoCa from different perspectives?
• Final reflections on pan-European assessment for orphan drugs

 

10:30 Morning Coffee

11:00 Technology and orphan drug development

Maria Pascual

Maria Pascual, Regulatory Affairs, Minoryx Therapeutics S.L.
View Bio

 • Experiences and perspectives on the various challenges in the development of orphan drugs & the available facilitating and accelerating toolbox
• Analysing the challenges associated with the data sharing and analysis for rare disease research
• Changes in market prospects for rare diseases following the improvement in efficiency of drug development
 

12:20 Networking Lunch

13:20 Improving patient access to orphan medicinal products

Jayne Spink

Jayne Spink, Chief Executive Officer , Genetic Alliance UK
View Bio

• Current developments of approaches to help educate orphan drug manufacturers and stake holders
• Highlighting the benefits of the collaboration of patient panels to provide a more targeted approach to orphan drug development.
• Exploring the influence of patient groups in providing early access of orphan treatments for rare disease cases where there’s no alternative
• Importance of investing in rare disease spaces to provide future opportunities
 

14:00 Building an educational digital community in rare diseases - a PAC first Mentality

Dan Donovan

Dan Donovan, Co-Founder & CEO, Clear Pharma
View Bio

• Overview and philosophy for developing and commercializing products in rare disease
• Why changing our mentality from taking to giving ultimately benefits the whole rare ecosystem?
• Sharing ways to help connect rare disease communities by addressing unmet needs
• Real world examples of effective and ineffective communication and its overall impact on orphan drug commercialization and marketing
 

14:40 Afternoon Tea

15:10 Charting the path to diagnosis for patients with rare diseases

Donatello Crocetta

Donatello Crocetta, VP, Global Head of Rare Immunology Franchise, Takeda
View Bio

• Discussing the importance of partnership between pharmaceutical, digital enterprises and patient associations
• Present the Global Commission to end the diagnostic odyssey of children with Rare diseases project
• Discussing the importance of the adoption of disruptive technology and advancement of diagnostic solutions in rare disease space
 

15:50 Patient Panel Discussion: perspective on patient engagement

David  Rose

David Rose, Business Development, Rare Revolution Magazine
View Bio

• Highlighting issues associated with engagement, including lack of reimbursement for their time

16:50 Chairman’s Closing Remarks and Close of Day Two

Rick Thompson

Rick Thompson, CEO, Findacure
View Bio

+

FEATURED SPEAKERS

Donatello Crocetta

Donatello Crocetta

VP, Global Head of Rare Immunology Franchise, Takeda
Jayne Spink

Jayne Spink

Chief Executive Officer , Genetic Alliance UK
Martina  Garau

Martina Garau

Associate Director, Office Of Health Economics
Michael Page

Michael Page

Executive Director, Portfolio Products, Alexion Pharmaceuticals Inc
Rick Thompson

Rick Thompson

CEO, Findacure
Sheela Upadhyaya

Sheela Upadhyaya

Associate Director - Highly Specialised Technologies , NICE - National Institute for Health and Care Excellence

Annamaria Merico

Head of Technology Transfer, Fondazione Telethon
Annamaria Merico

Anthony Hall

Co-founder, Findacure Development
Anthony Hall

Dan Donovan

Co-Founder & CEO, Clear Pharma
Dan Donovan

RareLife solutions is Dan’s second software and service focused venture. Having observed the often fractured, though always passionate stakeholders in rare diseases, Dan was inspired to create onevoice, providing rare disease specific “guided communities” thoughtfully designed to address several unmet needs while improving disease understanding and accelerating research.

Prior to rareLife and CPP, Dan founded Envision Pharma in 2001, serving as President through June 2011. Dan was the visionary behind the creation and development of Datavision, the market leader in medical publications technology. Envision Pharma was acquired by the United BioSource Corporation (UBC) in April 2008. At UBC, Dan was Senior Vice President Strategy and Market Development and a member of the Leadership Team.

Dan cut his teeth in industry at Pfizer serving in a variety of positions of increasing responsibility, ranging from sales to market research and marketing in the US domestic and international market place, culminating in his position as Director and European Team Leader living in Belgium. During his time at Pfizer, he played a pivotal role in the commercialization of some of the pharmaceutical industry's most successful product launches.
 

David Rose

Business Development, Rare Revolution Magazine
David  Rose

David Rose is an accomplished public speaker. He has an ultra-rare disease called Occipital Horn Syndrome. He discusses the ups and downs of living with an ultra-rare disease. He discusses all aspects of living with an ultra-rare disease, from studying to holidays. As well as his rare disease presentations, he also speaks on behalf of Great Ormond Street Hospital about his experiences using the hospital from a very young age up until his late teens.

Donatello Crocetta

VP, Global Head of Rare Immunology Franchise, Takeda
Donatello Crocetta

Senior International Manager with more than 19 years of leadership capabilities and in-depth pharmaceutical experience driving results in Medical Affairs, Marketing & Sales, Pricing and Reimbursement, Market Access at both global and local scale. Demonstrates ability to work effectively in matrix organizations and multicultural environments. Exposure to multiple therapeutic areas: Hematology, Inborn Errors of metabolism, Genetic diseases, Nephrology, Gastroenterology, Dermatology, Internal Medicine, Inflammation and Immunology, Cardiovascular, Rare Diseases, Metabolic Disorders, Primary and Secondary Immunodeficiencies, Hereditary angioedema.
Giacomo Baruchello, GM at Vertex Italy and former GM Shire SP Italy said about him: “Donatello has a remarkable background that includes science and business that makes him able to contribute on both fronts. A very committed person, his strong execution skills and mostly appreciated follow through on commitments attitude complete the profile of a promising future leader.”
Source: LinkedIn, public profile.
 

Eddie Pease

CTO, PharmaForesight.ai
Eddie Pease

Eddie has a Machine Learning MSc from UCL, where he was taught by Google DeepMind, learning the latest techniques in deep learning and reinforcement learning. He has had a broad experience in successfully implementing AI solutions a variety of different industries: from property to building a next job recommendation algorithm for a jobs website. Eddie is currently CEO of PharmaForesight.ai, a company which uses AI to help pharmaceutical companies assess the risk of clinical programs, and is passionate about the ability of AI to help inform better decisions in the pharmaceutical industry, ultimately benefitting patients.

 

Jayne Spink

Chief Executive Officer , Genetic Alliance UK
Jayne Spink

Jayne Spink is Chief Executive of Genetic Alliance UK and Chair of Rare Disease UK. Jayne has a BSc and PhD in genetics and postdoctoral experience in molecular genetics and cell biology. She left the research bench to join the Department of Health, initially as scientific secretary to the Gene Therapy Advisory Committee. As Head of Genetic Science, Safety and Regulation, she has worked on policy areas that have included gene therapy clinical research, stem cell research, genetic testing, genetics and insurance and ethics. Jayne is a former Associate Director of the Centre for Clinical Practice at NICE and has more than a decade of senior-level experience in the third sector. Immediately prior to joining Genetic Alliance UK, she served for 5 years as CEO of the Tuberous Sclerosis Association and served as the Multiple Sclerosis Society’s Director of Policy and Research (also for 5 years).

Katrin Jack

Sr. Manager Patient Access & Evidence Generation, Takeda Pharma AG
Katrin Jack

Katrin currently leads the patient access team at Takeda Switzerland. In her role she is responsible to negotiate price and access for Takeda’s portfolio. On top of that she drives the company´s local evidence strategy in close alignment with global and local cross-functional teams in order to optimise and maintain access. Prior to joining an affiliate, Katrin gained global knowledge in the pharmaceutical industry for orphan and non-orphan diseases having worked both in a market access and a strategy consulting company in London and Basel. She studied biomedical informatics and obtained a Master’s degree in healthcare management and economics in Milan.

Krzysztof Potempa

Founder and Director, BRAINCURES
Krzysztof Potempa

Krzysztof Potempa is Founder and CEO at BRAINCURES. He is a passionate computational neuroscientist with over 10 years of experience in deciphering biology from big data in academia and industry. In August 2016, he established BRAINCURES, to enable biology-driven patient-treatment matching (i.e., precision medicine) based on targets, compounds and biomarkers that are associated with their novel molecular framework for brain function. Their unique biological intelligence approach and Discovery Engine Platform processes to de-risk and accelerate drug discovery, pipeline management and clinical decision making have been recognized with the Beanstalks 2017 Best Mental Health Startup- and Sachs BEF18 Rising Stars- Award.

 

Maria Pascual

Regulatory Affairs, Minoryx Therapeutics S.L.
Maria Pascual

María is currently Chief Regulatory Officer at Minoryx Therapeutics, a clinical stage biotech company leading the development of new therapies for X-ALD and other Orphan CNS diseases, a group of rare diseases of genetic origin with a high unmet medical need. María is a regarded strategic regulatory expert with 20 years’ experience in regulatory affairs with an extensive track record of leading global registration activities for innovative new products. Prior to Minoryx, she was VP Regulatory Affairs and Quality at TiGenix bringing Alofisel from discovery to first allogenic stem cell product to receive EMA marketing authorization resulting in acquisition by Takeda. Board Member of EBE and member of EFPIA Regulatory Strategy Committee. Chaired regulatory working groups in various trade associations. Previous roles include, VP Regulatory Affairs and Quality at Cellerix, a stem cell therapy company on immune-based diseases. Holds a bachelor’s degree in Pharmacy and a Ph.D. in Immunology and worked in R&D at the Mayo Clinic, USA and the LUMC in the Netherlands.

Martina Garau

Associate Director, Office Of Health Economics
Martina  Garau

Martina’s current research includes methods and applications of Multi-Criteria Decision Analysis (MCDA) approaches in healthcare decision making; economic issues posed by the development and provision of treatments for rare diseases; value based assessments and HTA systems in high and middle income countries. This expertise informs projects undertaken for global pharmaceutical and life sciences companies, non-profit research organizations, charities and trade associations.
Martina joined the Office of Health Economics in 2004, following a placement at NICE in London. She has an MSc in Economics from the University of York and a first degree in economics from the University of Cagliari in Italy.

 

Michael Page

Executive Director, Portfolio Products, Alexion Pharmaceuticals Inc
Michael Page

At Alexion, Mike Page leads a global team which develops and executes of regulatory strategies across the company’s rare disease product portfolio. Prior to joining Alexion, Mike led the US Regulatory team for oncology at Eisai and the regulatory aspects of Eisai’s monoclonal antibody products. Prior to that, Mike was a regulatory affairs consultant at United BioSource Corporation, beforew which he was a Director of Regulatory Strategy at Pfizer, both in the UK and the US. Focusing mainly on late stage development and product registration, Mike has global experience in therapeutic areas including oncology, hematology, psychiatry, neurology, sexual health and addiction disorders.

Nick Sireau

Chair and CEO, AKU Society
Nick Sireau

Rick Thompson

CEO, Findacure
Rick Thompson

Dr Rick Thompson joined Findacure in 2015, after completing his PhD in Evolutionary Biology at the University of Cambridge. He began working as Findacure’s first Scientific Officer, helping to develop the charity’s proof of concept study for the innovative drug repurposing social impact bond. Having been promoted to CEO in May 2017, Rick now oversees the charity’s strategy and development, oversees major funding applications, and manages the team, while still maintaining Findacure’s scientific projects. Rick is always keen to speak about Findacure’s work, and aims to encourage industry engagement with rare disease patient groups, promoting an open and collaborative approach to rare disease research and patient support.

Sara Carlot

Global Medical Advisor - Rare Disease, Chiesi Farmaceutici S. p. A.
Sara Carlot

After a Bachelor degree in Molecular Biology, followed by a Master specialisation in Health Biology, I worked for the Scientific Forensic department of the Italian Police Force in Florence. Afterwards I worked for a Pharmaceutical company where I was responsible for both sales and marketing activities of their paediatric drugs portfolio. I then spent two years at the University of Amsterdam within the System Biology department where I carried research on cell cycle. In 2015 I joined Chiesi Farmaceutici as a Project Manager in the Rare Disease field and in 2017 I started my career as a Global Medical Advisor still in the rare Disease field specializing myself in the Advance Therapies Medicinal Products (ATMPs).

Sheela Upadhyaya

Associate Director - Highly Specialised Technologies , NICE - National Institute for Health and Care Excellence
Sheela Upadhyaya

Sheela Upadhyaya is currently the Associate Director of the Highly Specialised Technology program at NICE and is responsible for running the program to evaluate medicines and technologies for rare and ultra-rare conditions for commissioning in the NHS. She has extensive experience in understanding the issues that face companies and other stakeholders when trying to secure access for medicines for the orphan and ultra-orphan conditions. These include developing innovative access arrangements in liaison with industry, clinicians, patients and the NHS.
Sheela has co-authored several papers that discuss HTA methods for assessing value of orphan medicines and presented at many conference issue panels on the subject.
Prior to joining NICE, she commissioned rare and ultra-orphan disease services in the NHS delivering improvements through collaborating with industry, clinicians and patient groups. During that time, she successfully decommissioned failing services and seamlessly transferred the care of patients to better quality services.
Sheela has a passion for partnership working and believes that collaboration across the sector is the key to delivering high quality outcomes for all.

 

Tom Watson

Executive Vice President, Bionical Emas
Tom Watson

For many years, Tom has partnered with Pharma and Biotech companies to design their strategy for pre-approval access and develop global programs, allowing patients to gain access to often lifesaving treatments. Within this time, Tom has been involved in setting up and running over 200 global Early Access Programs.

Official Media Partner

Supporters

VENUE

Holiday Inn Kensington Forum

97 Cromwell Road , London, United Kingdom

Holiday Inn Kensington Forum is perfectly situated in one of London’s most luxurious and beautiful areas within South Kensington. 

The hotel is just 2 minutes walk from Gloucester Road tube station for convenient travel to Hyde Park, London Eye, Tower Bridge plus more of London’s top attractions. There are also easy and direct links to some major transport hubs including Victoria, Kings Cross St Pancras, Paddington and Heathrow. 

This distinctive hotel in south London has so much to offer to make all guests really feel at home. The latest Holiday Inn relaunch is not just about the new look and feel for the hotel but to offer guests more benefits during their stay including a pillow menu for extra comfort during their sleep and a curved shower rail for more spacious feel. 

In addition to our 906 rooms, all business guests can take advantage of our meeting and conference facilities including High Speed Internet Access and unlimited Starbucks coffee at The Academy. Our hotel’s professional event planners are on board to help take the hard work and stress away from planning your next event. 

So whether you in London on business or pleasure, make the Holiday Inn London Kensington Forum your first choice of hotel and book your accommodation for our lowest internet rate guarantee. 

A number of our clients have been approached by third party organisations offering to book hotel rooms. We would advise that you do not book through them as they are not representing the SMi Group. SMi Group books all hotel rooms directly. If you are approached by a third party organisation then please contact us before making any bookings. If you have already booked a hotel room using a third party organisation, we would highly recommend contacting the hotel you were booked into to ensure a booking has been made for you. We would also advise you to please check the terms and conditions of the booking carefully.
HOTEL BOOKING FORM

Preliminary Attendees 2019

Download

Speaker Interview with Tom Watson

Download

Speaker Interview with Eddie Pease

Download

Speaker Interview with Donatello Crocetta

Download

Co-chair Letter Invite from RICK THOMPSON, CEO, Findacure

Download

Orphan Drugs and Rare Diseases Conference 2019 Workshop

Download

Orphan Drugs and Rare Diseases Conference 2019 Programme

Download

SPEAKER BIOGPRAHIES

Download

Orphan Drugs and Rare Diseases 2019 Brochure

Download

PAST ATTENDEE LIST for Orphan Drugs & Rare Diseases

Download

2016 Orphan Drugs Conference Presentation by Cydan

Download

2016 Orphan Drugs Conference Presentation by INC Research

Download

2017 Orphan Drugs Conference Presentation by SANOFI

Download

2017 Orphan Drugs Conference Presentation by Idorsia Pharmaceuticals

Download

2018 Orphan Drugs Conference Presentation by MHRA

Download

2018 Orphan Drugs Conference Presentation by AstraZeneca

Download

Media Partners


Rare Revolution Magazine

Official Media Partner
http://www.rarerevolutionmagazine.com

Giving RARE a voice Rare Revolution Magazine is dedicated to providing exceptional articles of interest to the rare disease community. We provide a platform to the fantastic patient groups and charities that support over 7000 different rare conditions. This free subscription digital magazine means international access to all. You will find compelling voices from rare disease advocates and patients, articles from clinical, research and pharmaceutical teams and the latest in ‘RARE’ advancements. Our community is growing both virtually and through our local networks and ecosystems. Be part of the #rarerevolution. To receive Rare Revolution Magazine in your inbox visit www.rarerevolutionmagazine.com to subscribe for free. For content queries email: editor@rarerevolutionmagazine.com For membership enquiries: cdevaal@rarerevolutionmagazine.com For sales and advertising: drose@rarerevolutionmagazine.com


Gene Therapy Net

Official Media Partner
http://www.genetherapynet.com

Gene Therapy Net is the information resource for basic and clinical research in gene therapy, and the site serves as a network in the exchange of gene therapy information and breaking news items. Visitors can keep track of the latest scientific papers, conference announcements, gene therapy jobs, regulations and guidelines

Media Partners


Swiss Biotech Association

Supporters
http://www.swissbiotech.org/

The Swiss Biotech Association (SBA) is the national industry association for biotechnology, including pharmaceuticals, diagnostics, agriculture, food, cosmetics, environmental biotechnology, and specialty chemicals. Members are companies active in modern biotechnology, such as R&D, Production, Marketing and Sales, Finance, Services and Consulting. SBA provides a networking platform for Life Science clusters, academic and federal institutions the like. Founded in March 1998, the Association grows steadily.


Pharmaceutical Outsourcing

Supporters
http://www.pharmoutsourcing.com

Pharmaceutical Outsourcing, the journal dedicated to pharmaceutical and biopharmaceutical contract services. With regular sections on contract manufacturing, contract research, contract packaging, formulation/development services, contract analytical testing, APIs, stability testing, clinical research and other areas, we bring the most complete coverage of trends and issues in the industry to our 15,000 readers in North America.


Pharmacircle

Supporters
http://www.pharmacircle.com

PharmaCircle is an innovative knowledge management company serving the current and future global leaders in the Pharmaceutical and Biotechnology related industries. PharmaCircle is a one stop information and analysis source for pipeline, products, clinical trials, drug delivery technologies, deals and acquisitions, company financials, venture capital investments, product sales, pharmaceutical services, news, patents and more….


Labiotech.eu

Supporters
https://goo.gl/DRE2Gp

Labiotech.eu is the leading digital media covering the European Biotech industry. Over 100,000 monthly visitors use it to keep an eye on the business and innovations in biotechnology. Hope you'll enjoy reading our stories!


Farmavita

Supporters
http://www.farmavita.net/

Farmavita Net is professional community and network of pharmaceutical licensing and business development executives, innovators and researchers
Farmavita.Net is the pharmaceutical licensing, technology transfer and regulatory affairs network. We are managing the marketplace of offers and demand for pharmaceutical Dossiers, know-how and technologies. Members of Farmavita.Net network usually find a number of attractive solutions for business development, alliances, joint ventures, co-development and co-marketing of pharmaceutical products. Farmavita.Net is not just a pure Internet portal. We manage a number of regional associates. We are connecting the dynamic network of few hundreds members / pharmaceutical companies interested in license-in and license-out opportunities.


Biocompare

Supporters
http://www.biocompare.com

Biocompare.com is the leading resource for up-to-date product information, product reviews, and new technologies for life scientists. Biocompare combines an in-depth knowledge of life science products and new technologies with the power of the Internet to offer scientists the most dynamic, relevant, and innovative media-based marketplace for life science information.


American Pharmaceutical Review

Supporters
http://www.americanpharmaceuticalreview.com

Start receiving your free copy today. American Pharmaceutical Review is a review of the drug pipeline from the late discovery phase through manufacturing. American Pharmaceutical Review prides itself on having the most relevant, unbiased and informative editorial in the industry. You will find that all of our editorial is highly technical and written by government agencies, consultants, academics, and large pharmaceuticals companies. American Pharmaceutical Review covers several key topics that are important to drug production:Separations and purification, Drug Delivery, Biopharmaceutical Processing, Biopharmaceutical Development, Formulation development, Manufacturing, Microbiology, Instrumentation, Spectroscopy


SelectScience

Supporters
http://www.selectscience.net/register?utm_source=Media-Partner&utm_medium=Website&utm_campaign=SMI

SelectScience is an independent, online information resource for the worldwide scientific community, and the home of trusted information for laboratory scientists. Discover the latest drug discovery and development technologies, products and techniques with product reviews, videos, application notes and news articles. Become a member for free today.


Pharmalicensing

Supporters
http://www.pharmalicensing.com

Pharmalicensing (www.pharmalicensing.com) is the premier biopharmaceutical Open Innovation resource designed for professionals involved with partnering, licensing and business development worldwide. Actively supporting all forms of partnering and in- and out-licensing activities, Pharmalicensing utilizes the unique online Showcase Profiling & Discover services, as well as its renowned Partnering Search service leveraging its global network of industry experts, to enable companies to identify and engage with appropriate partners around the world. Pharmalicensing is actively utilized by many tens of thousands of industry professionals each month. Pharmalicensing is a division of Cognis Group, Inc


Drug Discovery Today

Supporters
http://www.drugdiscoverytoday.com/

Drug Discovery Today covers the whole of the preclinical drug discovery process. The reviews are cutting edge, written by experts in their respective fields and cover all aspects of drug discovery from genomic and proteomic approaches, computational drug design, medicinal chemistry and the translation of these sciences to therapies.


pharmaphorum

Supporters
http://www.pharmaphorum.com

pharmaphorum drives innovation within the pharmaceutical industry, by bringing healthcare together through a suite of media services that help produce and disseminate thought leadership, combined with an online platform for communicating messages to a global audience.Visit www.pharmaphorum.com

SAVE TO


Outlook Calendar  OUTLOOK CALENDAR
Google Calendar  GOOGLE CALENDAR
ICal Calendar  ICAL CALENDAR
Yahoo! Calendar  YAHOO! CALENDAR

Holiday Inn Kensington Forum

97 Cromwell Road
London SW7 4DN
United Kingdom

Holiday Inn Kensington Forum

Holiday Inn Kensington Forum is perfectly situated in one of London’s most luxurious and beautiful areas within South Kensington. 

The hotel is just 2 minutes walk from Gloucester Road tube station for convenient travel to Hyde Park, London Eye, Tower Bridge plus more of London’s top attractions. There are also easy and direct links to some major transport hubs including Victoria, Kings Cross St Pancras, Paddington and Heathrow. 

This distinctive hotel in south London has so much to offer to make all guests really feel at home. The latest Holiday Inn relaunch is not just about the new look and feel for the hotel but to offer guests more benefits during their stay including a pillow menu for extra comfort during their sleep and a curved shower rail for more spacious feel. 

In addition to our 906 rooms, all business guests can take advantage of our meeting and conference facilities including High Speed Internet Access and unlimited Starbucks coffee at The Academy. Our hotel’s professional event planners are on board to help take the hard work and stress away from planning your next event. 

So whether you in London on business or pleasure, make the Holiday Inn London Kensington Forum your first choice of hotel and book your accommodation for our lowest internet rate guarantee. 

HOTEL BOOKING FORM

Title

SubTitle
speaker image

Content


Title


Description

Download


WHAT IS CPD?

CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

CPD AND PROFESSIONAL INSTITUTES

There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

GLOBAL CPD

Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

CPD Certificates

We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

Event Title

Headline

Text
Read More

I would like to speak at an event

I would like to attend an event

I would like to sponsor/exhibit at an event

SIGN UP OR LOGIN

Sign up
Forgotten Password?

Contact SMi GROUP LTD

UK Office
Opening Hours: 9.00 - 17.30 (local time)
SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
Registered in England No: 3779287 VAT No: GB 976 2951 71




Forgotten Password

Please enter the email address you registered with. We will email you a new password.

Thank you for visiting our event

If you would like to receive further information about our events, please fill out the information below.

By ticking above you are consenting to receive information by email from SMi.
Full details of our privacy policy can be found here https://www.smi-online.co.uk/privacy-legals/privacy-policy/.
Should you wish to update your contact preferences at any time you can contact us at data@smi-online.co.uk.
Should you wish to be removed from any future mailing lists please click on the following link http://www.smi-online.co.uk/opt-out